AFT new FDA approval could be a shot in the arm

AFT new FDA approval could be a shot in the arm
Analyst sentiment is positive after FDA approval of Maxigesic IV. (Image: Hyloris Pharmaceuticals)
Ben Moore
AFT Pharmaceuticals had a bump in share price on Wednesday morning following approval of its intravenous post-operative pain relief drug by the United States Food and Drug Administration.Following the announcement of the approval of Maxigesic IV, which came in overnight, the stock lifted 16 cents per share to $3.56 at the open on the New Zealand stock exchange (NZX), up from $3.40 at yesterday's close. It has since dipped to $3.50.AFT co-founder and managing director Hartley Atkinson said they were delighted to receive the second appro...

More Markets

Trump-era FX 'compounding' margin losses, analysts say
Retail

Trump-era FX 'compounding' margin losses, analysts say

"Liberation day" could make matters worse, says Kiwibank’s Kerr.

The simple strategy behind Dairyworks
Primary Sector

The simple strategy behind Dairyworks

Is New Zealand still fixated on the 1kg block of cheese?

NZ sharemarket up 0.3%, Tower dominates trading
Markets Market Close

NZ sharemarket up 0.3%, Tower dominates trading

The S&P/NZX 50 Index closed at 12,312.6, up 42.6 points or 0.35%.

Graham Skellern 01 Apr 2025
Behind the rise of shareholder activism
Markets

Behind the rise of shareholder activism

Activists can be seen as 'baddies', but a new report says there are benefits.